Impact of Magnesium Supplementation on Blood Pressure: An Umbrella Meta-Analysis of Randomized Controlled Trials.
Level 1 - systematic review of randomized trials
Umbrella meta-analysis of systematic reviews and meta-analyses of randomized controlled trials
PubMed 39280209 · doi:10.1016/j.curtheres.2024.100755
What was done
An umbrella meta-analysis was conducted across four databases (PubMed, Scopus, EMBASE, and Web of Science) from inception up to July 15, 2024. Eligible systematic reviews and meta-analyses examining the effect of magnesium supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in randomized controlled trials were synthesized using a random-effects model.
What was found
Ten meta-analyses covering 8,610 participants were included. Overall, magnesium supplementation significantly reduced SBP by -1.25 mmHg (95% CI: -1.98 to -0.51, P = 0.001) and DBP by -1.40 mmHg (95% CI: -2.04 to -0.75, P = 0.000). In subgroup analyses, doses of 400 mg/day or greater produced larger reductions (SBP ES = -6.38 mmHg; DBP ES = -3.71 mmHg), whereas interventions lasting 12 weeks or longer yielded modest reductions (SBP ES = -0.42 mmHg; DBP ES = -0.45 mmHg).
Why it matters
This umbrella review synthesizes conflicting previous meta-analyses to confirm that magnesium produces a statistically significant, dose-dependent lowering of blood pressure, providing clearer guidance on effective dosages for clinical and nutritional interventions.
Limits
The abstract does not report baseline blood pressure status, participant health conditions, magnesium formulations, adverse events, or adherence. As an umbrella review pooling existing meta-analyses, primary trials may overlap across included reviews, and confidence intervals or p-values for subgroup analyses were not provided.
Cited by
- supports Magnesium supplementation helps lower blood pressure.